Eli Lilly Stock Valuation Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Source: Fool
- Psychological Price Barrier: Eli Lilly's current share price of $903 is perceived as a psychological barrier; while many investors focus on absolute prices, true valuation should consider the earnings generated per dollar invested, indicating that the stock may be reasonably valued.
- Diversified Pipeline Advantage: Lilly's revenue and earnings outlook are heavily influenced by the rapid adoption of its dual GIP/GLP-1 agonists, Mounjaro and Zepbound, while its anti-amyloid antibody, Kisunla, and dermatology and immunology programs further diversify its portfolio, reducing the risk associated with reliance on a single product.
- Forward Earnings Multiple Discount: Despite the expansion of Lilly's product portfolio, its current forward P/E ratio remains significantly lower than the euphoric peaks of the initial GLP-1 hype cycle, suggesting that investors are paying less for expected future earnings compared to a few years ago, reflecting a lack of market recognition for its diversified business.
- Long-Term Investment Opportunity: As new drugs transition from clinical promise to billion-dollar commercial realities, Lilly's earnings base is set to expand, leading to a potential re-rating of its valuation multiples, making the current price of $925 an attractive entry point for long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1191.740
Low
950.00
Averages
1192
High
1500
Current: 1191.740
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Stock Valuation Analysis
- Stock Performance: Eli Lilly's stock has surged approximately 441.5% over the past five years, currently priced around $1,213, indicating strong performance; however, multiple valuation checks suggest the stock may be overpriced, prompting investors to carefully assess entry points.
- Cash Flow Forecast: Over the last twelve months, Eli Lilly generated about $8.6 billion in free cash flow, with the DCF model estimating an intrinsic value of approximately $1,591 per share, implying the current stock price is roughly 23.7% undervalued, providing potential upside for investors.
- P/E Ratio Analysis: Eli Lilly's P/E ratio stands at about 42.8x, significantly above the pharmaceutical industry average of 15.4x, although its tailored fair P/E ratio is approximately 39.2x, indicating that while investors are paying a premium for growth expectations, it is not excessively out of line with the company's profile.
- Market Expectations and Risks: While Eli Lilly's GLP-1 drugs bolster cash flow expectations, regulatory and pricing pressures may limit the premium investors are willing to pay, making the ability to sustain current cash flows and pipeline execution critical for future valuation.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Johnson & Johnson's CEO Focuses on Cancer Drugs Over Weight Loss Market
- Strategic Shift: CEO Joaquin Duato of Johnson & Johnson has stated that the company will not engage in the GLP-1 weight loss drug race, instead focusing on oncology and its large medical device business, a strategic shift aimed at reducing reliance on a single market and enhancing long-term stability.
- Investment in Cancer Drugs: Johnson & Johnson holds a strong market position in bone and lung cancer and has recently acquired a company with an attractive prostate cancer drug candidate, which not only enriches its product line but also provides diversified growth opportunities for the company.
- Medical Device Advantage: As one of the world's largest pharmaceutical companies, Johnson & Johnson is also a giant in the medical device sector, focusing on surgical items and new joints, which allows for a diversified investment portfolio that mitigates market risks compared to pure-play drug manufacturers.
- Financial Comparison: Johnson & Johnson's P/E ratio stands at 29x, significantly lower than Eli Lilly's 40x, while offering a 2.1% dividend yield compared to Eli Lilly's 0.6%, indicating that Johnson & Johnson may present better long-term value, especially for income-focused investors.
See More
Johnson & Johnson Sidesteps GLP-1 Drug Hype
- Market Dependency Issue: Eli Lilly's weight-loss drugs account for nearly two-thirds of its revenue, indicating a high reliance on a single market that could pose financial risks in the future.
- Strategic Shift: Johnson & Johnson's CEO Joaquin Duato opts not to chase the GLP-1 hype, instead focusing on oncology, particularly in bone and lung cancer drugs, demonstrating a strong commitment to its core competencies.
- Diversification Advantage: As one of the largest pharmaceutical companies globally, J&J also holds a significant position in the medical device sector, offering products like surgical items and new joints, which enhances diversification for investors.
- Valuation Comparison: Eli Lilly's P/E ratio exceeds 40x, while J&J's stands at 29x; although J&J is not cheap, its 2.1% dividend yield is significantly more attractive than Eli Lilly's 0.6%, making it a more appealing long-term investment option.
See More
Johnson & Johnson Avoids $100 Billion Weight Loss Market
- Market Dependency Issue: Eli Lilly's weight-loss drugs account for nearly two-thirds of its revenue, indicating a high dependency on a single market that could pose future financial risks.
- Strategic Shift: Johnson & Johnson opts not to chase the hot GLP-1 drugs, instead focusing on its core competencies in oncology, particularly in bone and lung cancer medications, showcasing its potential for diversified growth.
- Investment Attractiveness Comparison: Eli Lilly's P/E ratio exceeds 40x, while Johnson & Johnson's stands at 29x; although J&J is not cheap, its more attractive 2.1% dividend yield compared to Eli Lilly's 0.6% enhances its investment appeal.
- Long-Term Growth Potential: Johnson & Johnson's strong position in the medical device sector allows it to offer investors diversified options, mitigating the risks associated with a single drug market, which may lead to more stable returns in the long run.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Eli Lilly Stock Valuation Analysis
- Stock Performance: Eli Lilly's stock has surged approximately 441.5% over the past five years, currently priced around $1,213, indicating strong performance; however, multiple valuation checks suggest the stock may be overpriced, prompting investors to carefully assess entry points.
- Cash Flow Forecast: Over the last twelve months, Eli Lilly generated about $8.6 billion in free cash flow, with the DCF model estimating an intrinsic value of approximately $1,591 per share, implying the current stock price is roughly 23.7% undervalued, providing potential upside for investors.
- P/E Ratio Analysis: Eli Lilly's P/E ratio stands at about 42.8x, significantly above the pharmaceutical industry average of 15.4x, although its tailored fair P/E ratio is approximately 39.2x, indicating that while investors are paying a premium for growth expectations, it is not excessively out of line with the company's profile.
- Market Expectations and Risks: While Eli Lilly's GLP-1 drugs bolster cash flow expectations, regulatory and pricing pressures may limit the premium investors are willing to pay, making the ability to sustain current cash flows and pipeline execution critical for future valuation.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Johnson & Johnson's CEO Focuses on Cancer Drugs Over Weight Loss Market
- Strategic Shift: CEO Joaquin Duato of Johnson & Johnson has stated that the company will not engage in the GLP-1 weight loss drug race, instead focusing on oncology and its large medical device business, a strategic shift aimed at reducing reliance on a single market and enhancing long-term stability.
- Investment in Cancer Drugs: Johnson & Johnson holds a strong market position in bone and lung cancer and has recently acquired a company with an attractive prostate cancer drug candidate, which not only enriches its product line but also provides diversified growth opportunities for the company.
- Medical Device Advantage: As one of the world's largest pharmaceutical companies, Johnson & Johnson is also a giant in the medical device sector, focusing on surgical items and new joints, which allows for a diversified investment portfolio that mitigates market risks compared to pure-play drug manufacturers.
- Financial Comparison: Johnson & Johnson's P/E ratio stands at 29x, significantly lower than Eli Lilly's 40x, while offering a 2.1% dividend yield compared to Eli Lilly's 0.6%, indicating that Johnson & Johnson may present better long-term value, especially for income-focused investors.
See More
Johnson & Johnson Sidesteps GLP-1 Drug Hype
- Market Dependency Issue: Eli Lilly's weight-loss drugs account for nearly two-thirds of its revenue, indicating a high reliance on a single market that could pose financial risks in the future.
- Strategic Shift: Johnson & Johnson's CEO Joaquin Duato opts not to chase the GLP-1 hype, instead focusing on oncology, particularly in bone and lung cancer drugs, demonstrating a strong commitment to its core competencies.
- Diversification Advantage: As one of the largest pharmaceutical companies globally, J&J also holds a significant position in the medical device sector, offering products like surgical items and new joints, which enhances diversification for investors.
- Valuation Comparison: Eli Lilly's P/E ratio exceeds 40x, while J&J's stands at 29x; although J&J is not cheap, its 2.1% dividend yield is significantly more attractive than Eli Lilly's 0.6%, making it a more appealing long-term investment option.
See More
Johnson & Johnson Avoids $100 Billion Weight Loss Market
- Market Dependency Issue: Eli Lilly's weight-loss drugs account for nearly two-thirds of its revenue, indicating a high dependency on a single market that could pose future financial risks.
- Strategic Shift: Johnson & Johnson opts not to chase the hot GLP-1 drugs, instead focusing on its core competencies in oncology, particularly in bone and lung cancer medications, showcasing its potential for diversified growth.
- Investment Attractiveness Comparison: Eli Lilly's P/E ratio exceeds 40x, while Johnson & Johnson's stands at 29x; although J&J is not cheap, its more attractive 2.1% dividend yield compared to Eli Lilly's 0.6% enhances its investment appeal.
- Long-Term Growth Potential: Johnson & Johnson's strong position in the medical device sector allows it to offer investors diversified options, mitigating the risks associated with a single drug market, which may lead to more stable returns in the long run.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
